CD8A and neoplasm: Several preclinical studies have reported that anti-angiogenic agents have the potential to convert unfavorable immune microenvironments into favorable ones by reducing the number of tumor-associated macrophages and preventing CD8+ T-cells from infiltrating tumor cells [96].